Skip to main content

Published

Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial.
Jantarabenjakul W. The Lancet Regional Health - Southeast Asia 2025;:https://doi.org/10.1016/j.lansea.2025.100650.
[Strengthening mRNA vaccine development in LMICs is essential for enhancing global pandemic preparedness. Comvigen demonstrated non-inferiority immunogenicity to Comirnaty and had a comparable safety profile, supporting mRNA vaccine development for global access and pandemic preparedness.]
Freely available online

Age Groups
Adults
Older People
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Population Health
Staff Groups
Immunisation
Public Health Doctor
Public Health Specialist